Literature DB >> 10353335

Site and event specific increase of striatal adenosine release by adenosine kinase inhibition in rats.

D R Britton1, J Mikusa, C H Lee, M F Jarvis, M Williams, E A Kowaluk.   

Abstract

The effects of the systemically administered adenosine kinase (AK) inhibitor, 5'-deoxy-5-iodotubercidin (5'd-5IT) on the striatal adenosine (ADO) release evoked by the excitotoxin, kainic acid (KA) were examined using rat bilateral striatal microdialysis. Local KA perfusion of one rat striatum caused a significant ipsilateral elevation of striatal ADO levels compared to basal and contralateral (artificial CSF-perfused) striatal ADO levels. KA-evoked striatal ADO release was augmented in animals receiving systemic 5'd-5IT treatment (cumulative dose of 7.5 micromol/kg, i.p.) compared with i.p. vehicle controls. In contrast, 5'd-5IT administration had no significant effect on basal or contralateral (artificial CSF-perfused) striatal ADO levels. Thus, consistent with the hypothesis of 'site and event specific' potentiation of ADO by AK inhibitors, 5'd-5IT unilaterally enhanced ADO levels in the striatum where KA-induced excitotoxic injury evoked endogenous ADO release, but not at the contralateral uninjured striatum.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353335     DOI: 10.1016/s0304-3940(99)00280-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

1.  The effect of ABT-702, a novel adenosine kinase inhibitor, on the responses of spinal neurones following carrageenan inflammation and peripheral nerve injury.

Authors:  R Suzuki; L C Stanfa; E A Kowaluk; M Williams; M F Jarvis; A H Dickenson
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  Cell and gene therapies for refractory epilepsy.

Authors:  Detlev Boison
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

3.  Profound hypothermia after adenosine kinase inhibition in A1AR-deficient mice suggests a receptor-independent effect of intracellular adenosine.

Authors:  Christoph Eisner; SooMi Kim; Alexandra Grill; Yan Qin; Marion Hoerl; Josephine Briggs; Hayo Castrop; Manfred Thiel; Jurgen Schnermann
Journal:  Pflugers Arch       Date:  2016-12-14       Impact factor: 3.657

4.  Nucleoside transporter subtype expression: effects on potency of adenosine kinase inhibitors.

Authors:  C J Sinclair; A E Powell; W Xiong; C G LaRivière; S A Baldwin; C E Cass; J D Young; F E Parkinson
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 5.  Modulators of nucleoside metabolism in the therapy of brain diseases.

Authors:  Detlev Boison
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

Review 6.  Adenosine kinase: exploitation for therapeutic gain.

Authors:  Detlev Boison
Journal:  Pharmacol Rev       Date:  2013-04-16       Impact factor: 25.468

7.  Adenosine kinase is a new therapeutic target to prevent ischemic neuronal death.

Authors:  Detlev Boison; Hai-Ying Shen
Journal:  Open Drug Discov J       Date:  2010-01-01

Review 8.  Adenosine kinase: A key regulator of purinergic physiology.

Authors:  Detlev Boison; Michael F Jarvis
Journal:  Biochem Pharmacol       Date:  2020-11-06       Impact factor: 5.858

9.  The Effect of Endogenous Adenosine on Neuronal Activity in Rats: An FDG PET Study.

Authors:  Fiona E Parkinson; Soumen Paul; Dali Zhang; Shadreck Mzengeza; Ji Hyun Ko
Journal:  J Neuroimaging       Date:  2016-04-15       Impact factor: 2.486

10.  Intracerebral microdialysis of adenosine and adenosine monophosphate - a systematic review and meta-regression analysis of baseline concentrations.

Authors:  Stevie van der Mierden; Sergey A Savelyev; Joanna IntHout; Rob B M de Vries; Cathalijn H C Leenaars
Journal:  J Neurochem       Date:  2018-09-27       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.